Importance of background rates of disease in assessment of vaccine safety during mass immunisation with pandemic H1N1 influenza vaccines.
Black S, Eskola J, Siegrist CA, Halsey N, MacDonald N, Law B, Miller E, Andrews N, Stowe J, Salmon D, Vannice K, Izurieta HS, Akhtar A, Gold M, Oselka G, Zuber P, Pfeifer D, Vellozzi C.
Black S, et al. Among authors: siegrist ca.
Lancet. 2009 Dec 19;374(9707):2115-2122. doi: 10.1016/S0140-6736(09)61877-8. Epub 2009 Oct 31.
Lancet. 2009.
PMID: 19880172
Free PMC article.